Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Heinz Peter Vollmers is active.

Publication


Featured researches published by Heinz Peter Vollmers.


Molecular Cancer Therapeutics | 2007

The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein

Stephanie Brändlein; Nicole Rauschert; Leo Rasche; Dreykluft A; Hensel F; Conzelmann E; Müller-Hermelink Hk; Heinz Peter Vollmers

Lipids are essential for normal and malignant cells during growth and differentiation. The turnover is strictly regulated because an uncontrolled uptake and accumulation is cytotoxic and can lead to lipoapoptosis: lipoptosis. The human monoclonal antibody SAM-6 binds to a cell surface receptor on malignant cells and to oxidized low-density lipoprotein (LDL). SAM-6 induces an excess of intracellular lipids, by overfeeding malignant cells with oxidized LDL, via a receptor-mediated endocytosis. The treated cells overaccumulate depots of cholesteryl esters and triglycerides. This lipid overaccumulation is tumor specific; nonmalignant cells neither bind the antibody nor harvest lipids after incubation. Because for both forms of apoptosis, the death domain dependent (“extrinsic”) and independent (“intrinsic”), the activation of proteases is crucial, we also investigated this pathway in more detail. It was found that shortly after internalization of antibody/oxidized LDL/receptor complex and formation of lipid depots, cytochrome c is released by mitochondria. Followed by this, initiator caspase-8 and caspase-9 and effector caspase-3 and caspase-6 are activated. The mechanism of mitochondrial trigger (e.g., by free fatty acids) is under investigation. However, the present data indicate that the SAM-6 antibody induces an intrinsic-like form of apoptosis by overfeeding malignant cells with lipoproteins. [Mol Cancer Ther 2007;6(1):326–33]


Oncology Reports | 2004

CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1.

Stephanie Brändlein; Tina Pohle; Christopher Vollmers; Ewa Wozniak; Nele Ruoff; Hans Konrad Müller-Hermelink; Heinz Peter Vollmers


Archive | 2005

Neoplasm-specific polypeptides and their uses

Hans Konrad Müller-Hermelink; Heinz Peter Vollmers; Frank Hensel


Archive | 2003

Neoplasm specific antibodies and uses thereof

Hans Konrad Mueller-Hermelink; Heinz Peter Vollmers


Archive | 2004

Methods of Identifying Neoplasm-Specific Antibodies and Uses Thereof

Heinz Peter Vollmers; Hans Konrad Müller-Hermelink


Archive | 2004

Adenocarcinoma specific antibody SAM-6, and uses thereof

Heinz Peter Vollmers; Hans-Konrad Müller-Hermelink


Archive | 2002

Receptor, the use thereof, and mouse antibodies

Hans Konrad Müller-Hermelink; Heinz Peter Vollmers; Frank Hensel


Archive | 1999

Substance for producing highly effective anti-tumour medicaments and corresponding method

Hans Konrad Müller-Hermelink; Heinz Peter Vollmers


Archive | 2009

Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same

Heinz Peter Vollmers; Stephanie Brändlein; Andreas Thalheimer; Leodevico L. Ilag; Barbara Power; Lishanthi Udabage; Frank Hensel; Frank Schoenen; Arndt-Rene Kelter; Christopher G. Hosking


Archive | 2005

Antigen of the Pm-2 Antibody and Use Thereof

Heinz Peter Vollmers; Frank Hensel

Collaboration


Dive into the Heinz Peter Vollmers's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leo Rasche

University of Würzburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ewa Wozniak

University of Würzburg

View shared research outputs
Researchain Logo
Decentralizing Knowledge